Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AFATINIB vs ARZERRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Afatinib is an irreversible, covalent-binding inhibitor of the Erb B family of tyrosine kinases, including EGFR (Erb B1), HER2 (Erb B2), Erb B3, and Erb B4. It blocks downstream signaling pathways such as PI3K/AKT and MAPK, leading to inhibition of tumor cell proliferation and survival.
Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.
First-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations,Treatment of metastatic squamous NSCLC progressing after platinum-based chemotherapy,Off-label: Use in other EGFR-mutant cancers (e.g., head and neck cancer, colorectal cancer) with specific mutations
Treatment of chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab,Treatment of previously untreated CLL in combination with chlorambucil,Treatment of relapsed CLL in combination with fludarabine and cyclophosphamide
40 mg orally once daily, continuously.
ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.
Terminal half-life is approximately 37 hours; supports once-daily dosing with steady-state achieved within 8 days.
Mean terminal elimination half-life after first dose is approximately 14 days (range 7–21 days) and increases with repeated dosing due to target-mediated clearance saturation; at steady state, half-life is ~24 days.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP3A4-independent pathways including flavin-containing monooxygenase (FMO). Excretion mainly via feces (85%) and urine (4%) as unchanged drug and metabolites.
Ofatumumab is a monoclonal antibody; metabolism is not through typical cytochrome P450 pathways. Clearance involves catabolism to peptides and amino acids.
Primarily fecal (85%) as unchanged drug and metabolites; renal excretion accounts for <4% of the dose.
Arzerra (ofatumumab) is eliminated primarily via the reticuloendothelial system and catabolism; renal excretion is minimal (<1% of dose as intact antibody). Biliary/fecal excretion has not been characterized, but as a monoclonal antibody, it is not significantly excreted in urine or feces.
Approximately 95% bound to plasma proteins, primarily to albumin.
As a monoclonal antibody, ofatumumab does not bind to plasma proteins; protein binding is negligible.
Volume of distribution is approximately 2300 L (about 33 L/kg for a 70 kg individual), indicating extensive tissue distribution.
Volume of distribution (Vd) is approximately 2.5–4.5 L, approximating plasma volume; does not distribute extensively into tissues (not reported in L/kg, but typical for Ig G1 monoclonal antibodies ~0.1–0.2 L/kg).
Oral bioavailability is approximately 92% relative to an oral solution; food reduces exposure, so take on an empty stomach.
Subcutaneous: ~60–70% absolute bioavailability; intravenous: 100%.
No starting dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to safety concerns.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or hemodialysis; use with caution.
Child-Pugh A: 40 mg once daily. Child-Pugh B: Reduce dose to 30 mg once daily. Child-Pugh C: Not recommended due to lack of data.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C); use with caution.
Safety and efficacy not established in pediatric patients; no specific dosing recommendations.
Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosing.
No specific dose adjustment recommended based on age alone; monitor renal function and tolerability, as elderly patients may have decreased renal function or comorbidities.
No specific dose adjustment required for elderly patients. Clinical studies included patients ≥65 years; overall efficacy and safety similar to younger adults, but higher incidence of serious infections and cardiac events observed.
None.
Hepatitis B virus (HBV) reactivation can occur with ofatumumab, leading to fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before initiation. Monitor HBV carriers during and after treatment.
Severe diarrhea (including dehydration and acute kidney injury),Interstitial lung disease (ILD)/pneumonitis,Severe hepatotoxicity (elevated liver enzymes, hepatitis),Left ventricular dysfunction (assess LVEF at baseline and during treatment),Severe bullous, blistering, and exfoliative skin reactions (e.g., Stevens-Johnson syndrome),Gastrointestinal perforation,Ocular toxicities (keratitis, conjunctivitis),Renal toxicity (proteinuria, nephrotic syndrome),Fetal harm (embryo-fetal toxicity),Drug interactions with CYP3A4 inducers or inhibitors
Infusion reactions (including anaphylaxis), prolonged cytopenias, progressive multifocal leukoencephalopathy (PML), intestinal obstruction, tumor lysis syndrome, and infections including hepatitis B reactivation.
None reported,Relative contraindications: pre-existing severe hepatic impairment, severe renal impairment, pregnancy, and breastfeeding
Known hypersensitivity (anaphylaxis) to ofatumumab or any of its excipients.
Take on an empty stomach (at least 1 hour before or 2 hours after food). Avoid grapefruit, grapefruit juice, and Seville oranges as they may alter drug metabolism. High-fat meals reduce absorption.
No known food interactions. Take with or without food.
Afatinib is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of major congenital malformations, including cardiac, skeletal, and neural tube defects based on animal studies showing embryotoxicity and teratogenicity at doses below human exposure. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and impaired renal function due to inhibition of EGFR signaling critical for fetal development.
ARZERRA (ofatumumab) is a human monoclonal antibody. Ig G molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), there is a potential risk of fetal B-cell lymphocytopenia and impaired immune response. Data from animal studies are insufficient. The drug should be avoided during pregnancy unless the benefit clearly outweighs the risk.
No human data on afatinib excretion in breast milk; however, animal studies indicate drug presence in milk. M/P ratio is unknown. Due to potential for serious adverse effects in breastfed infants, breastfeeding is contraindicated during therapy and for at least 2 weeks after the last dose.
It is unknown whether ofatumumab is excreted in human milk. Human Ig G is present in breast milk, but levels are low. Due to the potential for serious adverse reactions in the breastfed infant (including B-cell depletion), breastfeeding is not recommended during therapy and for at least 6 months after the last dose. No M/P ratio is available.
No specific dosing guidelines for pregnancy. Pharmacokinetic changes (increased volume of distribution, altered metabolism) may occur but studies have not established dose adjustments. The drug should be avoided in pregnancy unless benefit outweighs risk; if used, consider therapeutic drug monitoring if available.
No specific dose adjustment guidelines are established for pregnancy. The pharmacokinetics of monoclonal antibodies may be altered due to increased plasma volume and clearance in pregnancy, but no formal studies have been conducted. Use caution and consider therapeutic drug monitoring if available.
Monitor for diarrhea, which can be severe; consider loperamide and hydration. Assess for interstitial lung disease (ILD) and hepatotoxicity. Dose reduction required for severe renal impairment (Cr Cl 15–29 m L/min). For patients with EGFR exon 19 deletion or exon 21 L858R mutation, first-line use improves PFS. Avoid P-glycoprotein strong inducers (e.g., rifampin) during treatment.
ARZERRA (ofatumumab) is a monoclonal antibody targeting CD20 used in relapsing multiple sclerosis. First dose reactions are common; premedicate with corticosteroids, antihistamines, and antipyretics. Monitor for infections, especially hepatitis B reactivation. Contraindicated in active hepatitis B. Administer as subcutaneous injection; injection site reactions frequent. Live vaccines contraindicated during and after treatment until immune reconstitution.
Take afatinib at least 1 hour before or 2 hours after a meal.,Do not crush, chew, or split tablets; swallow whole with water.,Seek medical help for severe or persistent diarrhea, cough, or difficulty breathing.,Avoid grapefruit and Seville oranges during treatment.,Report signs of liver problems (yellowing skin/eyes, dark urine).,Use effective contraception during and for 2 weeks after stopping therapy.,Avoid direct sunlight exposure; use sunscreen.
Report any signs of infection (fever, chills, cough, painful urination) promptly.,Inform your doctor of any history of hepatitis B infection.,You will receive premedication before the first dose to reduce allergic reactions.,Do not receive live vaccines during treatment or until your doctor confirms immune recovery.,Common side effects include injection site reactions, headache, and fever.,ARZERRA is given as an injection under the skin; rotation of injection sites is recommended.
"Afatinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), both undergo metabolism via CYP450 enzymes. Afatinib is a moderate inhibitor of CYP2D6 and may also inhibit CYP1A2 and CYP3A4, while fluvoxamine is a known inhibitor of CYP1A2 and CYP2C19. Coadministration can lead to increased fluvoxamine concentrations due to inhibition of its metabolism, potentially resulting in enhanced serotonergic effects such as serotonin syndrome, as well as increased adverse effects like nausea, dizziness, or QT prolongation."
"The combination of afatinib, a tyrosine kinase inhibitor, with pantoprazole, a proton pump inhibitor (PPI), can lead to reduced absorption of afatinib due to elevated gastric pH. Afatinib exhibits pH-dependent solubility, and higher gastric pH decreases its dissolution and bioavailability, potentially reducing its therapeutic efficacy. This interaction may result in suboptimal plasma concentrations of afatinib, increasing the risk of treatment failure in patients with non-small cell lung cancer."
"Estrone, an estrogen hormone, may induce the expression of UDP-glucuronosyltransferase (UGT) enzymes, which are involved in the glucuronidation and subsequent clearance of afatinib. This induction can lead to a decrease in afatinib serum concentrations, potentially reducing its efficacy in the treatment of non-small cell lung cancer. Clinically, this interaction may result in suboptimal therapeutic outcomes unless the afatinib dose is adjusted."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AFATINIB vs ARZERRA, answered by our medical review team.
AFATINIB is a Tyrosine Kinase Inhibitor Antineoplastic that works by Afatinib is an irreversible, covalent-binding inhibitor of the Erb B family of tyrosine kinases, including EGFR (Erb B1), HER2 (Erb B2), Erb B3, and Erb B4. It blocks downstream signaling pathways such as PI3K/AKT and MAPK, leading to inhibition of tumor cell proliferation and survival.. ARZERRA is a Antineoplastic, Monoclonal Antibody that works by Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AFATINIB and ARZERRA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AFATINIB is: 40 mg orally once daily, continuously.. The standard adult dose of ARZERRA is: ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AFATINIB and ARZERRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AFATINIB is classified as Category C. Afatinib is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of major congenital malformations, including cardiac, skeletal, and neura. ARZERRA is classified as Category C. ARZERRA (ofatumumab) is a human monoclonal antibody. IgG molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.